skip to main content

HPV 18 Cervical Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGynaecological CancersHPV 18 Cervical CancerSCE Medical Oncology

A fit patient has persistent cervical adenocarcinoma after chemoradiotherapy. The tumour has PD-L1 combined positive score 4, there is no contraindication to bevacizumab, and no previous systemic treatment has been given for persistent disease. Which regimen matches NICE TA939?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Pembrolizumab plus platinum-paclitaxel, with optional bevacizumab

Option B is correct: TA939 uses pembrolizumab with platinum-taxane chemotherapy, adding bevacizumab when appropriate, for PD-L1 CPS at least 1. Option A is a later-line alternative rather than this appraised regimen. Option E omits chemotherapy. Option D omits concurrent pembrolizumab, and option C is not the TA939 cervical-cancer regimen.

Reference: NICE TA939: pembrolizumab combination for cervical cancer. https://www.nice.org.uk/guidance/ta939/chapter/1-Recommendations